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Passive therapy with neutralizing human monoclonal antibodies (mAbs) could be an effective therapy against severe acute respiratory
syndrome coronavirus (SARS-CoV). Utilizing the human immunoglobulin transgenic mouse, XenoMouse®, we produced fully human SARS-
CoV spike (S) protein specific antibodies. Antibodies were examined for reactivity against a recombinant S1 protein, to which 200 antibodies
reacted. Twenty-seven antibodies neutralized 200TCID50 SARS-CoV (Urbani). Additionally, 57 neutralizing antibodies were found that are likely
specific to S2. Mapping of the binding region was achieved with several S1 recombinant proteins. Most S1 reactive neutralizing mAbs bound to
the RBD, aa 318–510. However, two S1 specific mAbs reacted with a domain upstream of the RBD between aa 12 and 261. Immunoglobulin
gene sequence analyses suggested at least 8 different binding specificities. Unique human mAbs could be used as a cocktail that would
simultaneously target several neutralizing epitopes and prevent emergence of escape mutants.
© 2006 Elsevier Inc. All rights reserved.Keywords: Severe acute respiratory syndrome coronavirus; SARS-CoV; Human monoclonal antibodiesIntroduction
Coronaviruses (CoV) historically are known to cause
relatively mild upper respiratory tract infections, and account
for approximately 30% of the cases of the common cold in
humans (Baker, 2004). However, a recently identified CoV,
severe acute respiratory syndrome coronavirus (SARS-CoV),
causes severe respiratory distress in humans leading to mortality
in approximately 10% of infected individuals (Baker, 2004;
Rota et al., 2003, www.who.int/csr/sars/). In the year 2003,
SARS-CoV established efficient human to human transmission
resulting in several super-spreading events. By the end of the⁎ Corresponding author. Fax: +1 312 996 6415.
E-mail address: bprabhak@uic.edu (B.S. Prabhakar).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.09.029outbreak in July of 2003, SARS-CoV was responsible for 774
deaths and 8096 cases worldwide involving 29 countries (www.
who.int/csr/sars/). Since the conclusion of the SARS outbreak,
several reports in 2004 of confirmed cases of SARS of unknown
origin indicate that the environmental threat of SARS-CoV still
exists (www.who.int, The Chinese SARS Molecular Epide-
miology Consortium, 2004). SARS-CoV-like virus can be
isolated from horseshoe bats in China, and researchers postulate
that this is the natural reservoir for the virus (Lau et al., 2005; Li
et al., 2005b). SARS-CoV-like virus remains present in
intermediate wild animal hosts, such as the Himalayan palm
civet, raising the possibility of re-emergence of SARS-CoV
infection in humans (Chan et al., 2006; Peiris and Yuen, 2004).
Because of the lingering threat, it is prudent to develop effective
modalities of pre- and post-exposure treatments against SARS-
CoV infection.
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proved effective in bringing the outbreak under control, a
targeted and effective treatment for SARS-CoV remains highly
desirable. In humans, SARS-CoV peak viral load is reached
approximately about 10 days post onset of symptoms, thus
offering an opportunity for effective post-exposure treatment
(Chen et al., 2005, 2006). One modality of treatment that may
limit virus replication and thus the spread of the virus is passive
immunization with pre-formed neutralizing human monoclonal
antibodies (mAbs). Such a treatment during the prodromal
phase of the disease could aid in rapid clearance of virus and
limit poor clinical outcome and person to person spread, without
the adverse effects associated with use of corticosteroids, animal
sera or human sera.
SARS-CoV mediates infection of target cells via the spike
(S) protein expressed on the surface. SARS-CoV S protein is a
type one transmembrane glycoprotein divided into two func-
tional domains S1 (aa 15–680) and S2 (aa 681–1255) (He et al.,
2004; Li et al., 2005a). The S1 domain mediates the interaction
of the S protein with its cellular receptor, angiotensin-
converting enzyme 2 (ACE2) (Li et al., 2003). A region of S1
consisting of 193 amino acids forms the receptor binding
domain (RBD) which is responsible for ACE2 binding (Wong et
al., 2004). More recently, a receptor binding motif (RBM)
within the RBD, consisting of 70 amino acids, has been shown
to directly contact the tip of ACE2 (Li et al., 2005a). The S2
domain of the S protein contributes to infection of the target cell
by mediating fusion of viral and host membranes through a
conformational change in which two conserved helical regions
(HR1 and HR2) of the S protein are brought together to form a
six-helix bundle fusion core (He et al., 2005a; Huang et al.,
2002; Ingallinella et al., 2004; Tripet et al., 2004). Therapies
that can disrupt interactions of these domains with the virus
receptor will likely confer protection and be of therapeutic
value.
The S protein serves as the main antigen that elicits
protective immune responses, including neutralizing antibodies
in infected humans and animals (Bisht et al., 2004; Buchholz et
al., 2004; Chen et al., 2005; Greenough et al., 2005; He et al.,
2005b; Hofmann et al., 2004). Intranasal or intramuscular
application of a modified vaccinia virus Ankara (MVA)
expressing S protein into mice elicits SARS-CoV neutralizing
antibodies (Bisht et al., 2004). Immunization of mice with a
DNA vaccine encoding the S sequence, devoid of the
cytoplasmic domain and/or the transmembrane domain, results
in the development of neutralizing antibodies as well as both
CD4+ and CD8+ T cell responses (Yang et al., 2004). However,
it is the humoral (IgG) component of immunity and not the
cellular component that inhibits viral replication (Yang et al.,
2004). In fact, transfer of immune serum from immunized mice
to naive mice reduces SARS-CoV titers following viral
challenge (Subbarao et al., 2004). Together, these studies
demonstrate that primarily Abs are responsible for protection
against SARS-CoV replication, and indicate the potential
therapeutic value of passive transfer of neutralizing Abs against
SARS-CoV. The immunogenic property of the S protein,
including its ability to induce neutralizing antibodies and itsessential role in viral attachment and fusion, make it an ideal
target for developing effective immunotherapy against SARS-
CoV infection.
Passive therapy with human immunoglobulin can confer
immediate protection without the deleterious effects asso-
ciated with the use of animal or chimeric Abs containing
animal derived amino acid sequences (Lonberg, 2005). There
are several ways to produce human mAbs; the method used
here takes advantage of the transgenic XenoMouse® (Amgen
British Columbia, Inc, Burnaby, BC). In the XenoMouse®,
the mouse immunoglobulin (Ig) genes are replaced with genes
encoding human Igs. Unlike using human B cells from
infected or immunized individuals, these animals allow
repeated immunization with the antigen of choice to induce
B cells capable of producing a wide array of functionally
relevant mAbs with high affinities against the antigen without
further antibody engineering (Rathanaswami et al., 2005).
This approach is highly flexible and allows extensive
screening to select for different antibodies with unique
properties. Furthermore, human mAbs can be directly
produced from the hybridomas or the Ig genes can be cloned
and used to generate recombinant cell lines, if necessary.
Because of these advantages, we used the XenoMouse® to
produce a large panel of neutralizing human mAbs against
SARS-CoV S protein with distinct specificities.
Results
Production of human neutralizing antibodies against S protein
XenoMouse® IgG2κ animals were immunized with the
ectodomain of S protein (Tor2) and hybridomas produced by
standard protocol (Davis et al., 2004). Initially, hybridomas
were grown to exhaustion and supernatants tested against a
recombinant S protein S-V5-HIS (Tor2), and counter-screened
against OVA-V5-HIS protein as a control. A large primary
screen was followed by an additional secondary screen that
resulted in the identification of 666 hybridomas capable of
producing human antibodies (Abs) specific to SARS-CoV S
protein with a minimum OD value of 0.3 (Table 1). These
666 Abs showed a wide range of binding efficiencies as
determined by ELISA, many yielding saturating OD values of
4.0 and greater (Table 1). From the initial screening, the
highest reacting 576 Abs were selected, further tested and
characterized.
These 576 Abs were examined for their reactivity with the S1
domain of the S protein (Urbani) containing aa 12–672. This
screening identified 200 Abs that were specific to the S1 domain
of the S protein with reactivity ranging from 0.171 to 1.817
(Fig. 1). Samples with OD values greater than 2× the average
background value (0.0825) were considered positive (Fig. 1).
Human Abs derived from XenoMouse® effectively neutralized
SARS-CoV (Urbani)
All S1 protein reactive Abs were tested for their ability to
neutralize SARS-CoV in a microneutralization assay. Twenty-
Table 2
Likely binding region of human Abs
ELISA reactivity a Group
designation b
Number of
Abs c
Number
neutralizing d
Likely binding
region e
All S1-IgG
fragments
1A 13 9 318–510
12–672 3A 1 0 510–672
12–672, 12–510 2A 4 1 12–261
12–672, 12–510,
318–510
1B 45 14 318–510
12–672, 261–672 3B 2 0 510–672
12–510 2B 29 2 12–261
12–510, 318–510 1C 41 0 318–510
318–510 1D 29 1 318–510
Total 165 27
a Fragments with which Abs react.
b Group designation determined based on likely binding region and fragment
reactivity.
c Number of total Abs that reacted with designated S1-IgG fragments.
d Number of these Abs that completely neutralized 200TCID50-SARS-CoV
(Urbani).
e Likely binding region of Ab group determined by differential fragment
reactivity.
Table 1
Reactivity with the ectodomain of S protein (aa 12–1193)
OD values a V5-S-HIS b V5-OVA-HIS c
OD>0.0 1152
OD>0.1 893 439
OD>0.2 739 94
OD>0.3 688 22
OD>0.4 657 11
OD>0.5 620 7
OD>0.6 593 6
OD>0.7 565 6
OD>0.8 541 6
OD>0.9 520 6
OD>1.0 508 4
OD>1.5 438 3
OD>2.0 401 3
OD>2.5 375 3
OD>3.0 352 2
OD>3.5 298 2
OD>4.0 136 0
a S positive supernatants with shown OD value or with greater.
b S positive supernatants accumulate from highest OD to lowest OD.
c Number of supernatants in each group that reacted with control V5-OVA-
HIS.
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neutralization (Table 2). As mentioned, the XenoMouse® was
immunized with the full ectodomain of the S protein. Though
this analysis has focused on the reactivity of Abs to S1, the
remaining 376 S1 non-reactive Abs were examined in a
microneutralization assay. An additional 57 Abs were found
that completely neutralized 100TCID50 SARS-CoV (Urbani)
(data not shown). In addition, three Abs that reacted with the
HR2 domain were examined in a microneutralization assay;
however, they did not neutralize SARS-CoV (data not shown).
Differential reactivity of hybridoma supernatants with S1
fragments suggested several different regions of S protein
recognized by human antibodies derived from XenoMouse®
Recombinant S1 proteins with a human IgG1 Fc tag (12–672,
12–510, 261–510, 318–510) were produced in 293T cells and
purified to examine the differential binding and target region of the
S1 reactive Abs (Fig. 2). These 200 S1 reacting Abs were furtherFig. 1. Reactivity of HmAbs produced from hybridomas generated from
immunized XenoMouse® against S1-Ig fragments by ELISA. All S-V5-HIS
reactive Abs were tested against S1-Ig (12–672) coated recombinant protein.
The 200 Abs that reacted with S1-Ig (12–672) were then tested for reactivity
against three S1-Ig fragments (12–510, 261–510 and 318–510).analyzed for their reactivity with additional S1 protein fragments
by ELISA (i.e. 12–510, 261–672 and 318–510) (Fig. 1). The
smallest fragment encoding the minimal RBD 318–510 oftenFig. 2. Expression of overlapping fragments of the S1 domain of SARS-CoV S
protein. (A) Four plasmid constructs encoding different fragments of the S1
protein (12–672, 12–510, 261–672, 318–510) were transformed into MC 1061/
P3 cells and insert size confirmed by digestion with NheI and BamH1 and
analyzed on a 1% agarose gel. (B) Recombinant protein expression in transiently
transfected 293T cells was confirmed by Coomassie Blue staining of a 4–20%
SDS/PAGE gel.
96 M. Coughlin et al. / Virology 361 (2007) 93–102yielded the highest reactivity for most of the Abs tested relative to
the other fragments. Often 12–672 and 261–672 demonstrated the
least reactivity, suggesting that the region between 511 and 672
could partially mask epitopes within 318–510 in these S1
fragments (Fig. 1).
Antibodies that yielded OD values above 0.5 (165 Abs that
yielded approximately 6× above the background) were grouped
based on their reactivity with various S1 fragments (Table 2).
Comparison of the Ab reactivity across all S1 fragments
indicated that most Abs reacted within the RBD 318–510. Abs
that bound to 318–510 fell into four groups (group designation
1A–1D), based on their differential reactivity with the other S1
fragments (Table 2). The S1 fragments containing 511–672
possibly mask a dominant epitope(s) as represented by the high
number of Abs found in groups 1C and 1D that do not yield high
OD values with fragments containing this region. The difference
in S1 fragment reactivity suggested that the epitope(s)
recognized by Abs in groups 1C and 1D, which react with
12–510 and/or 318–510 fragments but lack reactivity with S1
fragments containing aa 511–672, are different than those of
groups 1A and 1B which do react with fragments containing this
region, though all group 1 Abs appear to bind within 318–510.
Further epitope mapping was attempted using overlapping
peptides derived from the 318–510 region of S1 domain
(provided by NIH). These peptides consist of 18 amino acids
with 10 amino acid overlap. None of the Abs showed significant
reactivity with any of the peptides indicating that the antibodies
recognized either conformational epitopes and/or required
glycosylation.
Thirty-three Abs were found to likely react between 12 and 261
(i.e. groups 2A and 2B). These Abs did not react with 261–672 or
318–510; however, they do react with 12–510, and group 2A
additionally reacts with 12–672 suggesting these Abs recognize
an epitope(s) within the 12–261 region. In addition, a few Abs
were found that react with the tail region of the S1 recombinant
protein likely binding between 510 and 672. These Abs reacted
solely with S1 fragments that included this tail region. The Abs in
groups 2 and 3 have varying reactivity with the S1 fragments
relevant to each group, which suggested that these Abs recognize a
different epitope or have a varying affinity that is affected by the
presence of 510–672 in group 2B as compared to 2A, and a lack
of aa 12–261 in group 3A as compared to group 3B, which
reacted to both 12–672 and 261–672 (Table 2). Mice were
immunized with full-length S protein; therefore, Abs that did not
react with the S1 domain were examined for their reactivity with
HR1 and HR2 domains in the S2 region. None of the antibodies
reacted with HR1 and three showed significant reactivity with
HR2. Two of the three HR2 binding Abs resulted in high OD
values (1.281 and 1.26) (data not shown).
Human Abs that recognized different regions of S1 varied in
their neutralizing potential. A significant proportion of the S1
reactive neutralizing Abs reacted with the RBD, consistent with
results obtained by other groups examining neutralizing Abs
against SARS-CoV (Greenough et al., 2005; He et al., 2005a, b;
He et al., 2004; Subbarao et al., 2004). Amajority of neutralizing
Abs fell into group 1A or 1B suggesting that these two groups
recognize a dominant neutralizing epitope(s). On the contrary,Abs that fall into groups 1C and 1D did not appear to recognize a
significant neutralizing epitope(s) since only 1 neutralizing Ab
out of 70 was identified between these groups (Table 2).
Three additional neutralizing Abs were found that most
likely bind to a region between amino acids 12 and 261 of the
S1 domain. This is analogous to other studies which have
shown neutralizing ability of Abs that bind upstream of the
known RBD (i.e. 130–150) (Greenough et al., 2005).
Antibodies directed to important neutralizing epitope(s)
accounted for approximately 16% of the total S1 specific Abs
generated, therefore the majority of the Abs appear to recognize
non-neutralizing epitope(s) within S1 (Table 2).
Purification and characterization of neutralizing human
monoclonal antibodies (mAbs) from XenoMouse® hybridomas
Neutralizing mAbs were cloned by limiting dilution and
confirmed by Ig gene sequencing. Twenty-four out of 27
previously identified neutralizing antibodies were recovered
and purified by protein A/G affinity columns, 19 of these were
subsequently confirmed as monoclonal by Ig gene sequencing.
Following purification, the reactivity of mAbs was retested
against the 318–510 fragment or 12–510, for those that failed to
bind to 318–510. The high ELISA reactivity to the relevant S1-
IgG fragments noted in the initial screening was maintained
after the purification of the mAbs (Fig. 3). Most mAbs
demonstrated a dose dependent binding in which OD values
decreased with increasing dilution of the antibody. Other mAbs,
such as 6B5 and 3H12, maintained high OD values possibly
indicating a relatively higher affinity; however, the overall
binding was somewhat lower than the other mAbs at the higher
concentrations, possibly reflective of the availability of the
epitope (Fig. 3).
Increasing dilutions of purified mAbs were tested for their
ability to neutralize 200TCID50 of SARS-CoV (Urbani). The
neutralizing titer of the antibody was defined as the lowest
concentration of mAb capable of completely neutralizing
200TCID50 of SARS-CoV. The mAbs varied in their neutraliz-
ing potential. Some mAbs neutralized SARS-CoVat concentra-
tions as low as 0.195 μg/ml. However, some mAbs were not
able to neutralize virus below a concentration of 12.5 μg/ml
(Table 3). This variance in neutralizing ability between mAbs
may be due to differences in affinities, fine binding specificities
and/or the extent of availability of the targeted epitope on virally
expressed native S protein. Often, the degree of reactivity in
ELISA did not correlate with the neutralization titer (Fig. 3 and
Table 3). This suggested the possible limited availability of
relevant epitopes in the virally expressed native S protein
relative to their availability in a particular recombinant S1-Ig
fragment, thus limiting neutralizing ability of certain mAbs.
Immunoglobulin (Ig) gene sequences suggested different
binding specificities among the human mAbs
Each of the purified mAbs was sequenced, and previous
group designations were further divided based on the
immunoglobulin gene sequence data. Sequence analysis
Fig. 3. Neutralizing mAbs were purified and examined for S1-Ig fragment reactivity in an ELISA. Recombinant proteins were coated on ELISA plates and increasing
dilutions of mAb tested for reactivity to the relevant S1 recombinant protein. (A) Group 1A purified mAbs reactivity to 318–510 recombinant protein. (B) Group 1B
purified mAbs reactivity to 318–510 recombinant protein. (C) Group 1D purified mAb reactivity to 318–510 recombinant protein. (D) Goup 2B purified mAbs
reactivity to 12–510 recombinant protein.
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specificities among the panel of mAbs. Unique binding
specificities were deduced from the usage of different V, J
and D gene sequences, in the case of the heavy chain (H chain).
There was preferential usage of A30 and JK4 rearrangement in
the light chain (L chain); 14 of the 19 mAbs used this
rearrangement for the L chain. The A30 V region was used 2
more times paired with different J segments. There was less
repetition in the H chain rearrangements, though there was
preferential usage of VH1-2, D3-10, JH4B rearrangement in the
H chain, which is used 8 times, all with the A30 JK4 rearranged
L chain. The next most frequent H chain rearrangement was
VH1–18, D1–26, JH4B, all these also paired with the A30, JK4
rearrangement of the L chain. In addition, there were several
more unique rearrangements on the H chain, usually paired with
unique rearrangements of the L chain (Table 3). This analysis
allowed the groups established earlier by ELISA reactivity to be
further subdivided based on the assumption that the different
gene rearrangements constitute the production of a unique
binding site. Therefore, for example, Group 1B was divided into
likely 4 different specificities based on different V(D)J usage in
the H and L chains (Table 3). The first group, 1B1, has the V1–
18, D1–26, JH4B H chain rearrangement paired with the A30,
JK4 L chain and though the group 1B2 also uses the A30, JK4
rearrangement on the L chain, the H chain rearrangement was
different, VH1–2, D3–10, JH4B; this likely results in the
recognition of a different epitope between groups 1B1 and 1B2(Table 3). The remaining members of the 1B group, 1B3 and
1B4, had unique H and L chain rearrangements and so likely
recognize their own unique epitopes (Table 3). The differences
in H chain and L chain rearrangements are important because
they influence the structure of the CDR3 region which confers
binding specificity.
Different rearrangements resulted in different CDR3 region
sequences in both the H and L chains (Fig. 4 and Table 3).
Our data demonstrated sequence differences within the CDR3
regions of several mAbs. The CDR3 region of group 1A1 and
1B2 is the same except for an S in the fourth position of the
H chain in group 1A1 rather than the germline encoded T as
in group 1B2 (Fig. 4 and Table 3). This change can alter the
binding specificity or affinity between these two groups of
mAbs, therefore the specific identification of the recognized
epitope is required to delineate any differences between these
groups of mAbs.
Two groups of mAbs showed changes in the CDR1 and
CDR2 regions. For example, 4G2 and 6C1 have three amino
acid differences within the CDR1 as compared to 4E2 although
they all fall into group 1A1 and have the same V(D)J usage
(Fig. 4). The mAb 6B1 has a single amino acid change in the
CDR2 region when compared to 3C7; again this change may
alter the affinity of 6B1 for the binding region within the S
protein resulting in slightly better neutralizing ability noted with
6B1 (Fig. 4). In addition, several mAbs have changes in one or
more of the four framework regions making up the structure of
Table 3
Summary of HmAbs reactivity, neutralizing titer and heavy (H) and light (L) chain usage
HmAb Group a Reactivity S1-IgG
(12–672, 12–510,
261–672, 318–510) b
Binding
region c
Neutralizing
titer 200TCID50
(μg/ml) d
H chain e L chaine H CDR3 f L CDR3f
4-E2 1A1 0.919, 1.518, 0.551, 1.839 318–510 0.781 VH1-2, D3-10, JH4B A30, JK4 GPHSFGSGSYPFDY QQYNSYPLT
4-G2 1A1 1.200, 1.662, 0.665, 1.811 318–510 0.781 VH1-2, D3-10, JH4B A30, JK4 GPHSFGSGSYPFDY QQYNSYPLT
6-C1 1A1 1.226, 1.586, 0.649, 2.405 318–510 0.781 VH1-2, D3-10, JH4B A30, JK4 GPHSFGSGSYPFDY QQYNSYPLT
3-A7 1B1 1.307, 1.523, 0.379, 1.964 318–510 0.195 VH1-18, D1-26, JH4B A30, JK4 GRYLDY LQYNSYPLT
5-A7 1B1 1.111, 1.449, 0.366, 1.997 318–510 0.781 VH1-18, D1-26, JH4B A30, JK4 GRYLDY LQYNSYPLT
5-D3 1B1 0.968, 1.316, 0.403, 2.020 318–510 0.195 VH1-18, D1-26, JH4B A30, JK4 GRYLDY LQYNSYPLT
5-D6 1B1 0.747, 1.313, 0.355, 2.117 318–510 0.195 VH1-18, D1-26, JH4B A30, JK4 GRYLDY LQYNSYPLT
6-B8 1B1 1.045, 1.704, 0.497, 2.133 318–510 0.781 VH1-18, D1-26, JH4B A30, JK4 GRYLDY LQYNSYPLT
4-A10 1B2 1.013, 1.524, 0.567, 1.792 318–510 3.125 VH1-2, D3-10, JH4B A30, JK4 GPHTFGSGSYPFDY QQYNSYPLT
6-C2 1B2 1.005, 1.603, 0.586, 1.849 318–510 0.781 VH1-2, D3-10, JH4B A30, JK4 GPHTFGSGSYPFDY QQYNSYPLT
3-F3 1B2 1.075, 1.349, 0.325, 1.887 318–510 0.781 VH1-2, D3-10, JH4B A30, JK4 GPHTFGSGSYPFDY QQYNSYPLT
5-A5 1B2 0.986, 1.187, 0.337, 2.310 318–510 0.195 VH1-2, D3-10, JH4B A30, JK4 GPHTFGSGSYPFDY QQYNSYPLT
6-B5 1B2 1.040, 1.324, 0.430, 2.087 318–510 3.125 VH1-2, D3-10, JH4B A30, JK4 GPHTFGSGSYPFDY QQYNSYPLT
5-E4 1B3 0.735, 1.199, 0.298, 2.275 318–510 12.5 VH1-2, N/A, JH4B A30, JK5 GRYLDY LQYNSYPIT
3-C7 1B4 1.092, 1.422, 0.357, 2.193 318–510 12.5 VH3-33, D2-2, JH4B L5, JK4 DPLGYCSSTSCSYFDY QQANNFPLT
6-B1 1B4 1.128, 1.166, 0.369, 2.093 318–510 3.125 VH3-33, D2-2, JH4B L5, JK4 DPLGYCSSTSCSYFDY QQANNFPLT
3-H12 1D 0.185, 0.318, 0.090, 1.304 318–510 3.125 VH4-59, D3-9, JH6B A30, JK3 DYDILTGYSNYYGMDV LQHNSYPFT
4-D4 2B1 0.258, 0.761, 0.103, 0.101 12–261 12.5 VH3-33, D4-17, JH4B A1, JK2 GGDGERFDY MQGTHWPPYVQ
1-B5 2B2 0.463, 1.292, 0.110, 0.191 12–261 0.195 VH3-33, N/A, JH5B A30, JK4 GDFYWFDP QQYNSYPLT
a Group designation based on fragment reactivity demonstrated previously and CDR3 sequence data.
b OD values obtained for each mAb against indicated fragments during the original screen.
c Likely binding region as determined previously by S1-IgG fragment reactivity.
d Concentration of mAb that completely neutralizes 200TCID50 SARS-CoV (Urbani).
e Ig gene segment usage.
f CDR3 sequences of each mAb.
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antigen binding pocket, changes within the framework region
can also contribute to binding specificity and affinity. Therefore,
these changes could result in a greater separation of the mAb
groups based on CDR regions and result in different specificity
for S protein or binding affinity for the same region. For
example, 5D6 belongs to the 1B1 group; however, 5D6 carries a
mutation in the framework 3 region, which could potentially
alter the recognition of S protein by this mAb and therefore set it
apart from the other members of the same group. Monoclonal
Abs 6B1 and 3C7 both belong to group 1B4; however, 3C7 has
a single amino acid change in framework region 3 which may
influence binding specificity and affinity, and therefore,
influence neutralizing capability (data not shown).
Discussion
Consistent with findings of other groups, we have shown that
immunization of XenoMouse® with recombinant S protein
resulted in the production of SARS-CoV specific neutralizing
Abs (Berry et al., 2004; Bisht et al., 2004; Buchholz et al., 2004;
Greenough et al., 2005; He et al., 2005a; He et al., 2004;
Hofmann et al., 2004). Moreover, we were able to use B cells
from these mice to generate a panel of neutralizing human
mAbs against SARS-CoV. The majority of our S1 reactive
mAbs reacted with the RBD (318–510) and likely neutralized
virus by blocking SARS-CoV S protein binding to ACE2 (Li
et al., 2003; Sui et al., 2004). Therefore, it is apparent that mAbs
produced in the current study recognize a critical domain notonly involved in the induction of an effective immune response
against SARS-CoV infection but also in viral attachment (He
et al., 2004; He et al., 2005a, b).
The Ig sequence analysis indicated that there was a
preferential usage of certain H and L chain genes namely, V1–
2 D3–10, JH4B and A30 JK4. There were several mAbs that
reacted with the S1 fragment but exhibited considerable
diversity in their H and L chain gene segment usage. This
suggested that these mAbs possibly recognized distinct epitopes
within a given domain. A majority of the neutralizing mAbs that
bound to 318–510 fell into groups 1A and 1B and exhibited a
similar S1 fragment binding pattern. However, the Ig sequence
data suggest that there could be up to 5 different binding
specificities within these two groups. For example, group 1B,
whose likely binding region is 318–510, could be divided into 4
different binding specificities based on different V(D)J rearran-
gements that yield unique CDR3 regions. In addition, variations
seen within the CDR3 sequences of mAbs with common Ig gene
usage, such as those seen between groups 1A1 and 1B2,
suggested that these mAbsmay bind to different epitopes or bind
the RBD epitope with varying affinity. Based upon the Ig
sequence analysis, we speculate that at least 8 different binding
specificities may be represented in our panel of mAbs; when
considering mutations found in CDR1, CDR2 and framework
regions, this could increase the number of different S1
specificities. The contribution of framework regions to Ab
binding is illustrated in the generation of a chimeric antibody to
respiratory syncytial virus (RSV) or TNF-α. When the CDR
regions of neutralizing murine mAbs were transferred to the
Fig. 4. Alignment of CDR sequences of neutralizing mAbs. Immunoglobulin genes of neutralizing antibodies were sequenced. Alignment of the amino acid sequences
of the heavy chain variable region (A) and light chain variable region (B) of all mAbs are depicted and arranged by common gene segment usage. Additions in mAb
sequences not contained in germ line sequence are annotated (#) in germ line sequence. N/A specific gene segment could not be identified.
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lost their representative neutralizing abilities (Tempest et al.,
1991, 1994). Therefore, the potential for changes that we saw in
the CDR and framework regions of our SARS S1 specific mAbs
may result in differences in binding specificity or affinity;
however, detailed epitope mapping is required to fully
characterize the fine binding specificity each of the mAbs.
In addition to antibodies that bind to the RBD, we isolated
other neutralizing mAbs (groups 2A and 2B) that can interact
with epitopes contained within amino acids 12–261, upstream
of the RBD. The presence of these neutralizing epitopes
demonstrates an important, yet unclearly defined role of this
region in SARS-CoV infection. Since this region has not been
implicated in binding of ACE2, these mAbs may prevent S
protein from acquiring the conformation required for mediating
fusion with the target membrane. Deletions within the first 300
aa of S1 eliminate fusion ability of S protein in a cell-to-cell
fusion assay while maintaining receptor binding function (Xiao
et al., 2004). The N-terminal region of S protein also seems to
play a role in the trimerization of S protein, a structure that may
be required for fusion (Xiao et al., 2004). Therefore, binding of
mAb to this region may interfere with important steps that
facilitate fusion. Further functional characterization of these
mAbs could yield information on the function of this region of
SARS-CoV S protein in viral entry.Screening of full-length S reactive, but S1 non-reactive,
Abs resulted in the identification of 57 additional neutralizing
Abs. These Abs likely react at the junction between S1 and
S2, within the S2 domain, or recognize important conforma-
tional epitopes that require the entire S protein. Since the S2
domain is involved in fusion of the viral and cellular
membranes, antibodies specific for regions within the S2
domain likely neutralize by inhibiting fusion. Such antibodies
will be of value to more carefully study the fusion events.
Moreover, the S2 domain is more highly conserved than the
S1 domain, and therefore S2 region reactive mAbs can be
combined with mAbs with distinct S1 binding specificities
that can prevent viral attachment to create a mixture of
antibodies with a broader range of specificity to more
effectively prevent infection by a wide range of clinical
isolates (Rota et al., 2003; Zhang et al., 2004). Additionally,
such an approach would significantly reduce or eliminate the
possibility of generating antigenic variants that might more
readily arise when a single mAb is used.
The mAbs produced in this study are unique in that they
express both human heavy and light chains. If proven to be of
therapeutic value, these antibodies will have a number of added
advantages. The IgG2 antibodies will be readily available in
extracellular body fluids (a known property of the IgG2
antibodies), IgG2 antibodies fail to activate the classical
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receptor (FcR) for IgG2 on macrophages and other phagocytes
to which antibodies can bind and mediate their functional
effects, they are unlikely to facilitate antibody dependent
enhancement (ADE) of viral infection through FcRs.
The immunogenicity of non-human derived Abs or chimeric
Abs with animal sequences could result in their rapid clearance
and reduce their efficacy (Lin et al., 2005). In addition, adverse
reactions, like those seen with chimeric or Abs from different
species, could be avoided by using human mAbs. Further, the
human mAbs are structurally intact and thus retain full
complement of their functional properties.
During an outbreak, the SARS-CoV can mutate and exhibit
antigenic variation. In fact sequence analysis indicates that the
clinical isolates could be divided into early, middle and late
isolates (Sui et al., 2005). The significance of this is
demonstrated in the ability of later isolates to escape
neutralization by a mAb that effectively neutralized an earlier
isolate (Yang et al., 2005). Therefore, it is important to produce
neutralizing mAbs that are effective against a wide range of
clinical isolates with antigenic diversity. Because of the
potential evolution of antigenic variants, an effective passive
therapy against SARS-CoV will likely contain a cocktail of
neutralizing mAbs that target different epitopes and/or steps in
the entry process, such as blocking receptor binding and fusion.
We believe that several of our mAbs can be used to prepare such
a cocktail for potential therapeutic use. In addition, identifying
neutralizing epitopes conserved over a range of clinical isolates
has significant implications for developing a more effective
vaccine largely devoid of non-neutralizing epitopes (Traggiai
et al., 2004).
Antibodies have proven important in the immune response
against SARS-CoV (Bisht et al., 2004; Buchholz et al., 2004;
Chen et al., 2005; Greenough et al., 2005; He et al., 2005b;
Hofmann et al., 2004; Zhang et al., 2006). Recovered patients
showed a higher Ab titer and neutralizing Abs against S protein
were maintained (Zhang et al., 2006). Therefore, utilizing
human mAbs is a viable therapeutic option for the treatment of
SARS-CoV infection. Abs that are capable of neutralizing in
vitro usually can also confer in vivo protection against a viral
challenge by reducing viral titer (Chen et al., 2005; Greenough
et al., 2005; Sui et al., 2004, 2005; Yang et al., 2005). Therefore,
these mAbs may be used for passive immunotherapy to provide
instantaneous protection to individuals infected with the SARS-
CoV in the case of re-emergence of SARS-CoV in the human
population.
Materials and methods
Virus and cells
SARS coronavirus (SARS-CoV) Urbani strain was obtained
from CDC. Virus was propagated in Vero cells in OptiPro serum
free medium (SFM) (Gibco, Carlsband, CA). The TCID50 value
was then determined by infecting 5×103 Vero cells/well in a 96
well plate with serial 1:10 dilutions of SARS-CoV. After 3 days
of incubation at 37 °C in a 5%CO2 humidified incubator, cellswere evaluated for cytopathic effect (CPE). The TCID50 value
was calculated by the Reed-Muench method.
Expression of S proteins
A cDNA encoding amino acids 1–1193 of the ectodomain of
the S protein (Tor2) (kind gift from Marco Marra and Caroline
Astell at the British Columbia Cancer Agency Genome
Sciences Centre) was cloned into the BaculoDirectTM Baculo-
virus Expression System (Invitrogen, Carlsband, CA) in frame
with a V5-HIS-tag. The protein was expressed in Sf9 cells and
purified using ProbondTM Nickel-Chelating Resin (Invitrogen,
Carlsband, CA).
The S1-IgG (Urbani) fragments used in screening and
domain mapping consisted of amino acids 12–672, 12–510,
261–672 or 318–510, in addition to the C5 signal sequence and
a human IgG Fc lacking the transmembrane domain (Wong et
al., 2004). The expression plasmids encoding different S1-Ig
fragments (i.e. aa 12–672, 12–510, 261–672, 318–510) were
transformed into MC1061/P3 ultracompetent cells (Invitrogen,
Carlsband, CA) and selected on tetracycline and ampicillin agar
plates. The constructs were confirmed by restriction analysis
using NheI and BamHI. The cDNAs encoding S1-Ig fragments
were transfected into 293T cells using a CaPO3 transfection kit
(Invitrogen, Carlsband, CA). Briefly, 293T cells were seeded
1 day prior to transfection, and the medium was changed the
following morning. The CaPO3 transfection procedure was
performed as follows: 10 μg DNA+50 μl CaCl2 (2 M)+450 μl
sterile H2O was mixed and added dropwise to 500 μl of HBS
while aerating (values are per transfected plate). Next day, the
cells were washed with PBS+1 mM CaCl2+0.5 M MgCl2 and
medium replaced with 293T SFM supplemented with 2 mM L-
glutamine and antibiotic/antimycotic (Gibco, Carlsband, CA).
Cells were incubated at 37 °C for an additional 24 h at which
time the medium was harvested and protease inhibitor tablets
added (Roche Diagnostics, Indianapolis, IN). The supernatant
was spun at 1500 rpm for 5 min, and the supernatant was mixed
with Protein-A sepharose beads (Santa Cruz Biotechnology,
Santa Cruz, CA) by rocking overnight at 4 °C. The beads were
then washed with PBS+CaCl2+MgCl2+0.5 M NaCl2 one time
followed by two additional washes with PBS+CaCl2+MgCl2.
Protein was eluted using 50 mM sodium citrate/50 mM glycine
at pH 2 and neutralized immediately using Tris–HCl (pH 9.5).
Protein was concentrated on Centricon filters (Millipore,
Bedford, MA) spinning at 3000 rpm for 1 h at 4 °C and
dialyzed overnight at 4 °C against PBS. Protein production was
verified by SDS-PAGE followed by Coomassie Blue (BioRad,
Hercules, CA) staining (Wong et al., 2004). The identity of the
protein was confirmed by western blotting using pooled sera
obtained from mice immunized with inactivated virus.
Generation of hybridomas from S protein immunized
Xenomouse®
Five micrograms of purified S protein was emulsified
in Titermax Gold adjuvant (Sigma, Oakville ON) and 6–
10 week old IgG2κ XenoMouse® animals were immunized
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tially using TiterMax Gold or alum (Sigma, Oakville ON) as
adjuvants. When the animals developed an anti-S antibody
response, a final boost in PBS was performed, 4 days later the
spleen and lymph cells were harvested, fused with P3
myeloma cells and HPRT+hybridomas were selected in
hypoxanthine-azaserine (HA) using a standard protocol
(Davis et al., 2004).
Antibody screening
Hybridoma supernatants from a total of 11,520 wells were
individually screened for S reactivity by ELISA against S-V5-
HIS. A secondary screen of 1152 wells against S-V5-HIS with a
counter screen against OVA-V5-HIS as a negative control was
performed. Hybridoma supernatants yielding OD values above
∼0.7 when tested against S-V5-HIS (Tor2) were further tested
against various S1-Ig fragments by ELISA. Initial screening
was carried out using the full-length S1-Ig (12–672). Briefly,
plates were coated with 50 ng/well of S1-IgG protein overnight
at 4 °C. The plates were blocked using 5% non-fat milk, 0.05%
Tween-20 for 1 h at room temperature, washed and 50 μl of
hybridoma supernatant (diluted 1:3.5) was added to each well
and incubated at room temperature for 1 h. After washing, 50 μl/
well of HRP conjugated goat-anti-human antibody was added
and incubated for 1 h at room temperature. Following washing,
the antibody binding was detected using 50 μl/well of substrate
(BD OptEIA, BD Biosciences Pharmigen, San Diego, CA) and
the reaction stopped using 25 μl of 10% HCl. The absorbance
was then read using a microplate reader (BioRad, Hercules, CA)
at 450 nm. The same procedure was followed for screening of
hybridoma supernatants (used at a dilution of 1:6) and purified
human monoclonal antibodies (mAbs) using the other S1-Ig
fragments.
Neutralization assay
The neutralizing ability of hybridoma supernatants against
SARS-CoV (Urbani) was tested using a microneutralization
assay. Vero cells were seeded at 5×103 cells per well in a 96
well plate in OptiPro SFM (Gibco, Carlsband, CA) a few hours
prior to the neutralization assay. Neutralizing ability of the Abs
in hybridoma supernatants was tested by mixing 50 μl of
hybridoma supernatant, diluted 1:2 in 50 μl of OptiPro SFM
(Gibco, Carlsband, CA) with 200TCID50 of virus in 100 μl of
medium for 1 h at 37 °C. Following incubation, 100 μl of the
antibody/virus mixture was added in duplicate to Vero cells and
incubated at 37 °C for 3 days. At this time, cells were visually
observed for cytopathic effect (CPE; indicated by rounding of
Vero cells) as an indicator of SARS-CoV infection. The same
assay was performed using 1:4 serial dilutions of purified
human monoclonal antibodies (mAbs).
Purification of human mAbs
Hybridomas that were positive for the production of
neutralizing antibodies were cloned by limiting dilution andthe clones cultured to produce large quantities of mAbs.
Supernatants from these hybridomas were purified using
Protein A/G affinity columns.
Sequencing of human mAbs
Total RNAwas purified from approximately 105 hybridoma
cells using an RNeasy Mini Kit (Qiagen, Mississauga, ON) as
per the manufacturer's instructions. The PCR amplification
protocol and primers have previously been described (Gallo et
al., 2000; Marks et al., 1991). V family primers were pooled or
used individually. Sequencing was performed by Lone Star
Labs (Houston, TX) using the BigDye™ Terminator Version
3.0 DNA sequencing kit (Applied Biosystems, Foster City, CA)
and ABI 3730 or 3100 automated sequencers (Applied
Biosystems, Foster City, CA).
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